Shortcuts

open access

Vol 8, No 3 (2009)
Case reports
Published online: 2009-11-02
Get Citation

The use of octreotide in the symptomatic treatment of patients with neuroendocrine tumours: a single-centre experience

Anna Kamińska, Barbara Brzezińska, Michał Kamiński, Roman Junik
Advances in Palliative Medicine 2009;8(3):113-120.

open access

Vol 8, No 3 (2009)
Case reports
Published online: 2009-11-02

Abstract

Neuroendocrine tumours (NETs) are a heterogeneous group of tumours originating from endocrine cells scattered throughout the body and which form the diffuse endocrine system. Functioning tumours produce hormones or catecholamines which are responsible for the characteristic clinical picture.
Surgery is the treatment of choice for patients with NETs, although it can rarely be radical. Somatostatin analogues play an important role in the drug treatment of NETs, as they effectively control the signs and symptoms of the excessive release of hormones by these tumours. Treatment with somatostatin analogues improves the quality of life for the patient and prolongs survival.
We report on four patients with neuroendocrine tumours managed with somatostatin analogues: one male patient with carcinoid syndrome; one female patient with clinical manifestations of functioning VIPoma; and two male patients with ectopic ACTH syndrome.

Abstract

Neuroendocrine tumours (NETs) are a heterogeneous group of tumours originating from endocrine cells scattered throughout the body and which form the diffuse endocrine system. Functioning tumours produce hormones or catecholamines which are responsible for the characteristic clinical picture.
Surgery is the treatment of choice for patients with NETs, although it can rarely be radical. Somatostatin analogues play an important role in the drug treatment of NETs, as they effectively control the signs and symptoms of the excessive release of hormones by these tumours. Treatment with somatostatin analogues improves the quality of life for the patient and prolongs survival.
We report on four patients with neuroendocrine tumours managed with somatostatin analogues: one male patient with carcinoid syndrome; one female patient with clinical manifestations of functioning VIPoma; and two male patients with ectopic ACTH syndrome.
Get Citation

Keywords

somatostatin analogues; octreotide; neuroendocrine tumours

About this article
Title

The use of octreotide in the symptomatic treatment of patients with neuroendocrine tumours: a single-centre experience

Journal

Advances in Palliative Medicine

Issue

Vol 8, No 3 (2009)

Pages

113-120

Published online

2009-11-02

Bibliographic record

Advances in Palliative Medicine 2009;8(3):113-120.

Keywords

somatostatin analogues
octreotide
neuroendocrine tumours

Authors

Anna Kamińska
Barbara Brzezińska
Michał Kamiński
Roman Junik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl